Healium Medical

Executive Summary

Healium Medical is an Israeli medtech startup developing a novel catheter-based ultrasound system for cardiac arrhythmia and hypertension ablation therapies. Its Dual-Mode Ultrasound Technology (DMUT) combines real-time imaging with therapeutic ultrasound, enabling non-contact lesion creation that automatically adjusts power based on tissue thickness. This approach aims to simplify ablation procedures, reduce reliance on fluoroscopy, and improve outcomes by providing real-time feedback. The company addresses a significant market: atrial fibrillation affects over 30 million people globally, and current radiofrequency or cryoablation catheters have limitations in precision and safety. Founded in 2020, Healium has raised $5 million in seed funding and is currently in preclinical development. The team brings expertise from leading Israeli medical device companies. With its miniaturized, multi-functional platform, Healium has the potential to disrupt the cardiac ablation market by offering a safer, more efficient, and more accessible tool for electrophysiologists. The company is likely to seek additional funding to advance to first-in-human studies and may pursue strategic partnerships with larger cardiovascular device firms.

Upcoming Catalysts (preview)

• Q2 2026Series A funding round70% success
• Q3 2026Publication of preclinical efficacy data80% success
• Q1 2027Strategic partnership with a cardiovascular device company40% success